RPTX Repare Therapeutics Inc. Forward P/S Multiple

reparerx.com (RPTX) - corporate logo

Repare Therapeutics is scaling its precision medicine portfolio while optimizing R&D expenses. The forward P/S trend in the GURU.Markets chart data helps assess business sustainability, where 9.60 reflects the latest metric value. Repare Therapeutics is based on the concept of synthetic lethality to combat cancer, and its experienced management effectively allocates resources to develop high-precision drugs.

RPTX (reparerx.com) Price to Expected Revenue Ratio history from 07/04/2022 to 02/07/2026

Repare Therapeutics Inc - analytical breakdowns and key metrics (RPTX)

- current price and projected stock value:
Stock Price Repare Therapeutics Inc.|RPTX - Analyst Target Range
- market capitalization data:
Market Capitalization Repare Therapeutics Inc|RPTX - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Repare Therapeutics|RPTX - Total Net Assets|Market Capitalization to Book Value Ratio reparerx.com|RPTX - Company Assets
- debt and liquidity data:
Total Debt to Capital Repare Therapeutics|RPTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Repare Therapeutics|RPTX - Aggregate Debt Obligations|Debt to Book Value Repare Therapeutics Inc|RPTX - Amount of Long-Term Liabilities|Company Short-Term Debts Repare Therapeutics|Quick Ratio reparerx.com
- net income and valuation multiples indicators:
RPTX - Company Net Income|Expected Profit Repare Therapeutics|RPTX - Company Value to Net Income|Forward P/E Multiple Repare Rx|RPTX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Repare Therapeutics Inc|RPTX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Repare Therapeutics|RPTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months reparerx.com|RPTX - Earnings per share increase in current year|Earnings growth forecast for next year Repare Therapeutics
- issuer revenue and sales details:
RPTX - Company Total Revenue|Company Projected Revenue Repare Therapeutics Inc.|RPTX - Price-to-Sales Ratio|Forward P/S Multiple Repare Therapeutics Inc
Summary company analysis:Repare Therapeutics Inc. (RPTX)
Product sample of reparerx.com

This indicator calculates the ratio of current market capitalization to expected revenue, measuring the degree of overvaluation of future cash flows and the sensitivity of business value to operating costs. By analyzing the forward P/S of Repare Therapeutics (RPTX) on GURU.Markets, an investor can assess the extent to which the long-term patent protection of Repare Therapeutics in oncology offsets the risk of capital freeze through high demand inertia.

Competing companies

Forward P/S Multiple GMAB (Genmab)|Projected Price to Revenue Exelixis Inc|Nuvalent Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera Corp|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (ORIC Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Therapeutics Inc RLAY|Forward P/S Multiple NRIX|Tyra Corp - Market Cap to Projected Revenue|Verastem, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales GLUE|CGEM: Forward Price-to-Revenue Multiple|Immuneering Corp - Price to Expected Revenue Ratio|CCCC: Forward P/S Multiple|Black Diamond Therapeutics, Inc - Forward Price to Sales|PMVP (PMV Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Karyopharm KPTI|Price-to-Projected Revenue Ratio Propanc Biopharma Inc (PPCB)|BGMS (Bio Green Med Solution Inc.) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience, Inc.)|Forward P/S Multiple Aileron Therapeutics Inc ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple